Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

Arthritis and Rheumatism

Volumn 64, Issue 12, 2012, Pages 3850-3855

  Krieckaert, Charlotte L ^a   Jamnitski, Anna ^a   Nurmohamed, Michael T ^a   Kostense, Piet J ^a   Boers, Maarten ^a   Wolbink, Gertjan ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT;

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RATING SCALE; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROGENITAL SYSTEM PARAMETERS;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGENETICS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870385642     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34680     Document Type: Article

References (20)

1. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al, on behalf of all Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
2. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN,. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33: 2398-408. (Pubitemid 46067817)
3. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011; 70: 266-71.
4. Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67: 1229-34.
5. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40. (Pubitemid 26036375)
6. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
7. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6. (Pubitemid 46477484)
8. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO III, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008; 58: 1921-30. (Pubitemid 351988083)
9. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012; 71: 88-91.
10. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
12. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
13. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67 Suppl III: iii2-25.
14. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57. (Pubitemid 36305610)
15. Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011; 372: 196-203.
16. Boers M, Kostense PJ,. Non-overlapping American College of Rheumatology response rates: a better way to report response in rheumatoid arthritis clinical trials. Arthritis Rheum 2010; 62: 3524-7.
17. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP,. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.
18. Lobo ED, Hansen RJ, Balthasar JP,. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68. (Pubitemid 39506617)
19. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6. (Pubitemid 46999794)
20. Calabrese LH,. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241-8. (Pubitemid 36519574)